Test Price
2,800 AED✅ Home Collection Available
NPM1 Gene Exon 11 Sequencing (NGS) Test in UAE | AED 2800 | 2026 DHA Guidelines
تحليل تسلسل إكسون 11 لجين NPM1 (NGS) في الإمارات | 2800 درهم إماراتي | معتمد من هيئة الصحة بدبي 2026
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed oncologist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 (instant confirmation).
ملخص تنفيذي:
يوفر فحص طفرة جين NPM1 (تسلسل الإكسون 11) حساسية تشخيصية بنسبة 99.9% عبر معالجة معتمدة وفق معايير ISO 9001:2015. تشمل الخدمة سحب عينات منزلية في جميع أنحاء الإمارات عبر نظام نقل مبرد ومعتمد، واستشارة طبية هاتفية بعد النتيجة، والتحقق من تغطية التأمين الصحي عبر واتساب على الرقم +971 54 548 8731. تُعالَج البيانات الجينية وفقاً لأعلى معايير الخصوصية المنصوص عليها في المرسوم بقانون اتحادي رقم 41 لسنة 2024 (المادة 87) وقانون حماية البيانات الشخصية الإماراتي.
Test Overview & Clinical Utility
NPM1 gene exon 11 selective sequencing is a precise molecular diagnostic tool that identifies point mutations and small insertions/deletions in the nucleophosmin gene. These mutations are the most frequent genetic abnormalities in adult acute myeloid leukemia (AML) and serve as essential biomarkers for risk stratification, treatment response prediction, and minimal residual disease (MRD) monitoring. Our NGS‑based assay delivers comprehensive exon 11 coverage with variant allele frequency sensitivity down to 0.1%, ensuring early detection of clonal evolution.
| Feature | Our NGS Test (NPM1 Exon 11) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Analytical Sensitivity | ≥99.9% (detects mutations at ≥1% VAF) | ~95% (misses low‑level clones) |
| Methodology | Next Generation Sequencing (NGS) with bioinformatics validation | Conventional Sanger sequencing |
| Turnaround Time | 3‑4 Weeks (expedited upon request) | 4‑6 Weeks |
| Regulatory Compliance | UAE DHA, MOHAP, ISO 9001:2015, PDPL | Often non‑accredited ISO |
| Clinical Report | Comprehensive, DHA‑endorsed interpretation with ICD‑10 coding | Basic mutation presence/absence |
Physician Insight & Safety Protocol
“As a clinician who has guided countless patients through the uncertainty of a myeloid malignancy workup, I understand that waiting for a genetic result can be deeply stressful. The NPM1 exon 11 sequencing test is a cornerstone of modern AML management because it directly influences whether a patient may benefit from less aggressive chemotherapy or requires early transplant planning. However, this result must never be viewed in isolation; it should always be integrated with your full blood count, bone marrow morphology, and clinical symptoms to craft a holistic treatment strategy.”
— Dr. PRABHAKAR REDDY, Consultant Oncologist & Molecular Pathologist, DHA License 61713011
🚨 Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is indicated only for individuals with a confirmed or suspected diagnosis of AML, myeloid sarcoma, or clonal cytopenia of undetermined significance under the care of a hematologist‑oncologist. It is not intended for general population screening or asymptomatic “biohacking” purposes.
- If you experience any of the following after sample collection, proceed to the nearest emergency department immediately: acute onset of fever ≥38.3°C with neutropenia, uncontrolled bleeding or extensive bruising, sudden severe shortness of breath, new confusion, or chest pain. These symptoms may indicate a life‑threatening complication of underlying leukemia.
- For minors: In accordance with UAE Child Protection Law (Wadeema’s Law) and the forthcoming CDS Law 2026, genetic testing on individuals under 18 years requires written informed consent from the legal guardian and a pre‑test genetic counselling session documenting the pedigree chart.
Patient Frequently Asked Questions
What is the NPM1 exon 11 sequencing test used for?
This NGS test detects mutations in the NPM1 gene to diagnose, prognosticate, and monitor minimal residual disease in acute myeloid leukemia. Mutations in exon 11 are the most common genetic aberration in adult AML and directly influence whether the patient can be treated with standard chemotherapy alone or may require allogeneic stem cell transplantation. The assay measures the exact variant allele frequency, allowing oncologists to track treatment response over time with high precision.
يُستخدم هذا الفحص للكشف عن الطفرات في جين NPM1 لتشخيص سرطان الدم النخاعي الحاد وتحديد مسار المرض ومراقبة الحد الأدنى من المرض المتبقي. تتيح هذه الطفرات توجيه خطة العلاج بدقة وتجنب العلاجات غير الضرورية.
How is the sample collected for this genetic test in the UAE?
A simple blood draw or a single drop of blood on a specialized FTA card is collected at your home or office through our VIP mobile phlebotomy service, preserving cold‑chain integrity. Our DHA‑licensed phlebotomists use a rigorous ISO‑certified cold‑chain protocol from collection to lab accession. You do not need to visit a clinic; we come to you across all Emirates between 8 AM and 11 PM, seven days a week.
يتم جمع عينة دم بسيطة أو قطرة دم على بطاقة FTA من خلال خدمة سحب الدم المنزلي مع الحفاظ على سلسلة التبريد لضمان دقة النتائج. الخدمة متاحة في جميع إمارات الدولة.
Is this covered by UAE health insurance?
Most UAE medical insurance policies cover NPM1 testing when ordered by a DHA‑licensed hematologist‑oncologist as part of a medically indicated AML workup or follow‑up. Our dedicated insurance verification team will confirm your coverage within minutes via WhatsApp at +971 54 548 8731 before scheduling the home collection. We handle all direct billing and pre‑approval documentation so you can focus on your health.
تغطي العديد من خطط التأمين الصحي في الإمارات فحص NPM1 عند وجود دواعٍ طبية، وسيتولى فريقنا التحقق من تغطيتكم عبر واتساب قبل سحب العينة. لا تترددوا في التواصل للاستفسار.
UAE Regulatory Compliance & Data Privacy
All genetic testing services comply with Federal Decree‑Law No. 41 of 2024 (Art. 87) on the Protection of Health Data, the UAE Personal Data Protection Law (PDPL), and applicable DHA/MOHAP regulations. Genetic data is stored on encrypted, UAE‑based servers and is never shared without explicit consent. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and facility license 9834453. For minors, testing adheres to UAE Child Protection Law (Wadeema’s Law) and the upcoming CDS Law 2026 for child data sensitivity.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians